Filter By Category
Archives
Share on -
AMUBARVIMAB
Generic Name: AMUBARVIMAB
ABSTRACT -
Amubarvimab is a human monoclonal antibody directed against the SARS-CoV-2 spike protein. It has been studied and used in combination with a second monoclonal antibody, romlusevimab, for treatment or prevention strategies in COVID-19 where viral variant susceptibility supports activity. A small-molecule structure is not applicable; the representation above is a monoclonal-antibody schematic.
DOSAGE -
Dosage should be determined only by a qualified healthcare professional.
Use depends on local authorisation, variant susceptibility, patient risk category, and combination regimen.
Administration has involved intravenous infusion with companion antibody therapy according to protocol or label.
Monitor during and after infusion for hypersensitivity and clinical worsening.
SIDE EFFECTS–
- Possible side effects include:
- Infusion-related reactions
- Fever or chills
- Nausea
- Vomiting
- Diarrhoea
- Fatigue
- Hypertension
- Dizziness
- Rash or pruritus
- Clinical worsening of COVID-19 can occur independent of treatment.
ALLRGIC REACTIONS–
- Hypersensitivity to amubarvimab or excipients may occur.
- Symptoms may include rash, urticaria, flushing, bronchospasm, hypotension, angioedema, or anaphylaxis.
- Important: Infusion must occur where allergic reactions can be managed promptly.
DRUG INTERACTIONS–
- CYP-mediated drug interactions are not expected.
- Other anti-SARS-CoV-2 monoclonal antibodies or antivirals should be coordinated according to guidelines.
- Vaccination timing should follow local public-health guidance after monoclonal antibody therapy.
- Patients should disclose all medicines and immune conditions.
PREAUTIONS–
- Confirm current variant susceptibility and local guidance before use.
- Use caution in patients with prior severe infusion reactions.
- Monitor high-risk patients for progression of COVID-19 after infusion.
- Safety in pregnancy and lactation should be evaluated clinically.
WARNINGS –
- Effectiveness may be reduced or absent against resistant SARS-CoV-2 variants.
- Severe infusion reactions can occur.
- Do not delay urgent care for worsening breathing, chest pain, confusion, or low oxygen levels.
- Keep out of reach of children.
Share on -
. Developed by